טוען...
Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease
After 15 years of research into Alzheimer's disease (AD) therapeutics, including billions of US dollars provided by federal agencies, pharmaceutical companies, and private foundations, there are still no meaningful therapies that can delay the onset or slow the progression of AD. An understandi...
שמור ב:
| הוצא לאור ב: | Br J Pharmacol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6715597/ https://ncbi.nlm.nih.gov/pubmed/30924124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14668 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|